Cabaletta Bio (CABA)

Executive Summary

Cabaletta Bio is a clinical-stage biotechnology company pioneering CD19-CAR T cell therapies for autoimmune diseases. Its lead candidate, CABA-201 (rese-cel), aims to provide deep and durable remissions with a single infusion. The company is advancing multiple Phase 1/2 trials across systemic lupus erythematosus (SLE), generalized myasthenia gravis (gMG), systemic sclerosis, and idiopathic inflammatory myopathies, with a Phase 2/3 trial in myositis already recruiting. Early data have shown encouraging safety and efficacy, including high rates of drug-free remission. With a robust pipeline targeting large autoimmune indications, Cabaletta is positioned to transform the treatment paradigm if CABA-201 demonstrates consistent success. The company's progress in 2026 includes expanded enrollment and potential interim data readouts that could de-risk the program and support regulatory interactions.

Upcoming Catalysts (preview)

• Q3 2026Interim data from RESET-SLE (SLE) or RESET-gMG (gMG) Phase 1/2 trials60% success
• Q4 2026Initiation of Phase 3 trial for myositis (following Phase 2/3) or regulatory update70% success
• Q3 2026FDA breakthrough therapy designation for CABA-201 in an autoimmune indication50% success